With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Statins do not help prevent Alzheimer’s disease, but another cholesterol-controlling drug just might. Obicetrapib blocks cholesteryl esters being transferred from the “good” high-density lipoproteins ...

Computational biology has put the human brain vasculature in its crosshairs. On July 23 in Neuron, scientists led by Andrew Yang, University of California, San Francisco, report a multiomic approach ...

The investigational drug obicetrapib blocks the transfer of cholesteryl esters from high- to low-density lipoprotein. In a cardiovascular disease trial, it reduced plasma p-tau217.

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

Scientists from academia, pharmaceutical companies, and healthcare analysis firms reached no consensus on a threshold for meaningfulness, but broadly agreed that meaningfulness should be determined ...

Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

A meta-analysis of nearly 20,000 participants calculated the prevalence of brain amyloid across age and cognitive status. A third of cognitively normal people over 70 have amyloid, and ApoE4 carriers ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...